Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price target reduced by Barclays from $24.00 to $14.00 in a research report sent to investors on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other research analysts have also weighed in on the stock. Wells Fargo & Company reissued an [...]
Barclays Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $14.00
